에서 실시간으로 운영 중이에요! 자세히 알아보기
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

상장 폐지됨

MRTX은(는) 2024년 1월 22일에 상장 폐지됐어요.

순위로 돌아가기
 

소개: Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

직원 수: 593

건강관리 제약 - 종합

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 0%
중립 0%
부정적 0%
긍정적
Zacks Investment Research
2년 전
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
중립
PRNewsWire
2년 전
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previously received treatment with a platinum-based regimen and an immune checkpoint inhibitor.
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
긍정적
CNBC
2년 전
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
긍정적
Zacks Investment Research
2년 전
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.